Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.37 |
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776024 | 0.92 | IMPDH2 (0.46) | BRAFLIMK2IMPDH2CNR1CREBBP | |
| SCHEMBL16776424 | 0.91 | DYRK1A (0.40) | BRAF | |
| SCHEMBL16776401 | 0.87 | BRAF (0.42) | BRAFLIMK2IMPDH2CNR1CREBBP | |
| SCHEMBL16775995 | 0.87 | BRAF (0.41) | BRAFLIMK2CNR1RPS6KA3RPS6KA2 | |
| SCHEMBL19365610 | 0.86 | BRAF (0.42) | BRAFLIMK2IMPDH2CNR1CREBBP | |
| SCHEMBL16775875 | 0.86 | RHOA (0.46) | BRAFLIMK2CREBBPBRD4GPR142 | |
| SCHEMBL16776226 | 0.85 | HTR2C (0.45) | RPS6KA3 | |
| SCHEMBL16776298 | 0.82 | RHOA (0.39) | BRAFRHOA | |
| SCHEMBL16776025 | 0.80 | CYP11B2 (0.38) | WNT3A | |
| SCHEMBL16776211 | 0.80 | RPS6KA3 (0.43) | RPS6KA3WNT3ARPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | BRAF 3419/4885LIMK2 3495/4885IMPDH2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.